Last updated: February 19, 2026
This report provides a comprehensive overview of Zepbound's (tirzepatide) current clinical trial status, market positioning, and future market projections. Data points include trial phases, disease indications, competitor landscape, and projected market growth for obesity and type 2 diabetes pharmacotherapies.
What is the Current Clinical Trial Status of Zepbound (tirzepatide)?
Zepbound, developed by Eli Lilly and Company, is an injectable medication approved for chronic weight management in adults with overweight or obesity. Its active pharmaceutical ingredient is tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.
Key Clinical Trial Findings and Approvals
- Primary Indication: Chronic weight management in adults with obesity (BMI $\geq$ 30 kg/m$^2$) or overweight (BMI $\geq$ 27 kg/m$^2$) with at least one weight-related comorbidity.
- FDA Approval Date for Weight Management: November 8, 2023.
- European Medicines Agency (EMA) Approval Date for Weight Management: November 15, 2023.
- Mechanism of Action: Tirzepatide stimulates insulin secretion, reduces glucagon secretion, enhances insulin sensitivity, and delays gastric emptying. It also targets appetite regulation in the brain.
Ongoing and Completed Clinical Trials
Eli Lilly is conducting and has completed numerous clinical trials for tirzepatide across various indications. The SURMOUNT program is central to Zepbound's development for weight management.
Table 1: Select Tirzepatide Clinical Trials for Obesity and Related Conditions
| Trial Name/Phase |
Indication |
Patient Population (N) |
Key Findings/Status |
Publication/Source |
| SURMOUNT-1 (Phase 3) |
Chronic Weight Management |
2,539 |
Achieved primary endpoint: significant mean percentage weight loss from baseline (20.9% for 15mg dose, 15.0% for 10mg dose) at 72 weeks. [1] |
New England Journal of Medicine |
| SURMOUNT-2 (Phase 3) |
Type 2 Diabetes and Obesity |
2,519 |
Met primary endpoint: significant reduction in HbA1c and mean percentage weight loss (10.0% for 10mg dose, 12.9% for 15mg dose) at 72 weeks. [2] |
The Lancet |
| SURMOUNT-3 (Phase 3) |
Obesity with insufficient weight loss on calorie-restricted diet |
783 |
In individuals with obesity who underwent a 12-week very low-calorie diet, those randomized to tirzepatide achieved significantly greater weight loss. [3] |
JAMA Network Open |
| SURMOUNT-4 (Phase 3) |
Weight Loss Maintenance |
832 |
In patients who achieved $\geq$5% weight loss in the initial 36 weeks, tirzepatide maintained weight loss compared to placebo over an additional 52 weeks. [4] |
Nature Medicine |
| SURMOUNT-OSA (Phase 3) |
Obstructive Sleep Apnea (OSA) |
~500+ |
Results published in November 2023 showed tirzepatide significantly reduced the Apnea-Hypopnea Index (AHI) in adults with moderate-to-severe OSA. [5] |
New England Journal of Medicine |
| SURMOUNT-CVS (Phase 3) |
Cardiovascular Outcomes in Type 2 Diabetes |
~15,000+ |
Trial ongoing, assessing cardiovascular benefits in patients with type 2 diabetes and established cardiovascular disease. Expected completion: 2027. [6] |
Eli Lilly & Company |
| SURMOUNT-ND (Phase 3) |
Diabetic Nephropathy in Type 2 Diabetes |
~1,000+ |
Trial ongoing, evaluating the effect of tirzepatide on kidney outcomes in patients with type 2 diabetes and diabetic kidney disease. [7] |
Eli Lilly & Company |
| SURMOUNT-HEART (Phase 3) |
Cardiovascular Outcomes in Overweight/Obese Adults |
~10,000+ |
Trial ongoing, assessing cardiovascular benefits in adults with overweight or obesity and established cardiovascular disease but without diabetes. [8] |
Eli Lilly & Company |
Note: Patient numbers are approximate and may vary slightly based on specific reporting.
What is Zepbound's Market Positioning and Competitive Landscape?
Zepbound enters a rapidly expanding market for obesity and type 2 diabetes treatments, characterized by a growing pipeline and increasing patient demand. Its dual GIP/GLP-1 mechanism offers a differentiated therapeutic profile.
Key Competitors and Their Market Presence
The GLP-1 receptor agonist class has seen significant growth, with semaglutide (Novo Nordisk's Ozempic and Wegovy) being the primary benchmark. Tirzepatide's dual agonism provides a potential advantage in efficacy.
Table 2: Key Competitors in the Obesity and Type 2 Diabetes Market
| Drug Name |
Active Ingredient |
Manufacturer |
Primary Indication(s) |
Mechanism of Action |
Status/Launch Date |
| Zepbound |
Tirzepatide |
Eli Lilly |
Obesity, Type 2 Diabetes |
GIP/GLP-1 Receptor Agonist |
Approved Nov 2023 (US) for obesity. Also approved as Mounjaro for T2D. |
| Wegovy |
Semaglutide |
Novo Nordisk |
Obesity |
GLP-1 Receptor Agonist |
Approved June 2021 (US) for obesity. |
| Ozempic |
Semaglutide |
Novo Nordisk |
Type 2 Diabetes |
GLP-1 Receptor Agonist |
Approved Dec 2017 (US) for T2D. Off-label use for weight loss is prevalent. |
| Saxenda |
Liraglutide |
Novo Nordisk |
Obesity |
GLP-1 Receptor Agonist |
Approved Dec 2014 (US) for obesity. |
| Contrave |
Bupropion/Naltrexone |
Currax Pharma |
Obesity |
Combination (Appetite) |
Approved Sept 2014 (US) for obesity. |
| Xenical |
Orlistat |
Roche/Generic |
Obesity |
Lipase Inhibitor |
Approved April 1999 (US) for obesity. |
| Retatrutide |
Retatrutide |
Eli Lilly |
(Investigational) Triple Agonist |
GLP-1/GIP/Glucagon Agonist |
In Phase 3 trials for obesity and NASH. Demonstrates higher weight loss in Phase 2. |
| Orforglipron |
Orforglipron |
Pfizer |
(Investigational) Oral GLP-1 Agonist |
GLP-1 Receptor Agonist |
Oral small molecule GLP-1 RA in Phase 3 trials for obesity. |
| Danuglipron |
Danuglipron |
Pfizer |
(Investigational) Oral GLP-1 Agonist |
GLP-1 Receptor Agonist |
Oral small molecule GLP-1 RA. Phase 3 trials ongoing for obesity. |
Market Share and Growth Drivers
The obesity drug market is poised for significant expansion. Factors driving this growth include:
- Increasing Prevalence of Obesity: Global rates of obesity continue to rise, creating a large unmet need.
- Improved Efficacy of New Pharmacotherapies: Drugs like tirzepatide and semaglutide offer substantially greater weight loss compared to older medications.
- Expanding Label Indications: Research into the broader health benefits of these drugs, including cardiovascular risk reduction and sleep apnea, is widening their therapeutic scope.
- Patient and Physician Awareness: Increased understanding of obesity as a chronic disease and the availability of effective treatments are driving adoption.
- Managed Care Reimbursement: While still a challenge, access through insurance coverage is gradually improving.
Eli Lilly's dual agonism with tirzepatide positions it strongly against single-agonist GLP-1 drugs by potentially offering superior weight loss and metabolic improvements. The ongoing SURMOUNT-CVS and SURMOUNT-HEART trials are critical for demonstrating cardiovascular benefits, which could further solidify Zepbound's market position and expand its addressable patient population.
What are the Market Projections for Zepbound and the Broader Obesity/Diabetes Market?
Market analysts project substantial growth for the obesity and type 2 diabetes pharmacotherapy markets, with Zepbound expected to capture a significant share.
Revenue Projections for Zepbound (Tirzepatide)
Eli Lilly has provided strong guidance for tirzepatide's commercial performance. Analyst consensus indicates robust sales growth.
- 2023 Revenue (Mounjaro & Zepbound combined): Approximately \$5.2 billion, primarily from Mounjaro (type 2 diabetes indication) launched in 2022. [9]
- 2024 Projected Revenue (Tirzepatide): Analysts forecast combined revenue for Mounjaro and Zepbound to exceed \$10 billion. Some projections range as high as \$15-20 billion within the next few years. [10]
- Peak Sales Potential: Estimates for peak annual sales of tirzepatide (across all indications) vary, with some analysts projecting over \$25 billion by the late 2020s. [11]
Broader Market Projections (Obesity and Type 2 Diabetes Pharmacotherapies)
The global obesity drug market is expected to grow from approximately \$2.5 billion in 2023 to tens of billions of dollars within the next decade.
- 2023 Market Size (Obesity Drugs): Approximately \$2.5 billion. [12]
- Projected Market Size (Obesity Drugs by 2030): Various sources project this market to reach between \$50 billion and \$100 billion by 2030, driven by the efficacy of newer drug classes. [13] [14]
- Type 2 Diabetes Market: The global market for T2D drugs is already substantial, exceeding \$40 billion and projected to grow steadily, with incretin-based therapies (including GLP-1 RAs and GIP/GLP-1 RAs) forming an increasing share. [15]
Factors Influencing Future Market Growth
- Expansion into New Indications: Successful outcomes in cardiovascular and kidney disease trials will significantly expand the eligible patient population and market value.
- Oral Formulations: Eli Lilly is developing an oral formulation of tirzepatide, which could further enhance patient convenience and market penetration. [16]
- Competition and Pricing Pressure: The entry of new competitors and potential genericization in the longer term will influence pricing dynamics.
- Reimbursement Policies: Broader insurance coverage and government formulary decisions will be critical for sustained market adoption.
- Long-Term Efficacy and Safety Data: Real-world evidence and long-term safety profiles will continue to shape physician prescribing habits and patient choices.
Eli Lilly's strategic development of tirzepatide, from type 2 diabetes to chronic weight management and ongoing expansion into cardiovascular and renal outcomes, positions Zepbound as a leading therapy with the potential to dominate a significant portion of the rapidly growing metabolic disease market.
Key Takeaways
- Zepbound (tirzepatide) has demonstrated significant efficacy in clinical trials for chronic weight management, achieving substantial mean percentage weight loss.
- Eli Lilly's extensive clinical trial program for tirzepatide includes ongoing studies assessing its benefits in cardiovascular outcomes, diabetic nephropathy, and obstructive sleep apnea, which could broaden its therapeutic applications and market reach.
- Zepbound enters a competitive landscape but holds a differentiated position as a dual GIP/GLP-1 receptor agonist, offering potential efficacy advantages over single-agonist GLP-1 drugs.
- The obesity drug market is projected for exponential growth, with Zepbound anticipated to capture a substantial share, contributing to combined annual revenues for tirzepatide that are expected to exceed \$10 billion in 2024 and reach over \$25 billion at peak.
Frequently Asked Questions
1. What are the key differences between Zepbound and Wegovy in terms of efficacy for weight loss?
Zepbound (tirzepatide) has demonstrated higher mean percentage weight loss in Phase 3 trials compared to Wegovy (semaglutide). For example, the SURMOUNT-1 trial reported a 20.9% mean weight loss with the 15mg dose of tirzepatide at 72 weeks, while Phase 3 trials for Wegovy reported approximately 15% mean weight loss with the 2.4mg dose at 68 weeks. [1] [17]
2. Is tirzepatide being investigated for conditions beyond obesity and type 2 diabetes?
Yes, Eli Lilly is actively investigating tirzepatide's potential in several other areas. Ongoing Phase 3 trials are evaluating its effects on cardiovascular outcomes in patients with type 2 diabetes (SURMOUNT-CVS) and in overweight/obese adults without diabetes (SURMOUNT-HEART), as well as its impact on diabetic nephropathy (SURMOUNT-ND). [6] [7] [8]
3. What is the projected timeline for an oral formulation of tirzepatide?
Eli Lilly is developing an oral formulation of tirzepatide. While specific launch dates have not been finalized, it is anticipated to be a significant market development. Details on the timeline are subject to ongoing clinical development and regulatory review. [16]
4. How does the dual GIP/GLP-1 mechanism of tirzepatide compare to single GLP-1 agonists like semaglutide?
Tirzepatide's dual action targets both GIP and GLP-1 receptors, which are key hormones involved in glucose metabolism and appetite regulation. This dual agonism is believed to contribute to its greater efficacy in both glucose lowering and weight reduction compared to GLP-1 receptor agonists alone, which primarily target the GLP-1 receptor. [18]
5. What are the primary challenges facing the widespread adoption of Zepbound and similar obesity medications?
Key challenges include the high cost of these medications, leading to issues with patient access and insurance reimbursement. Additionally, concerns about long-term safety, potential side effects (such as gastrointestinal issues), and the need for lifelong treatment to maintain weight loss remain significant considerations for patients and healthcare providers.
Citations
[1] Jastreboff, A. M., Hazuda, H. P., MacDonnell, P. J., Garvey, W. T., Nauck, M. A., DiPrima, A., & for the SURMOUNT-1 Investigators. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(2), 117–126. https://doi.org/10.1056/NEJMoa2206038
[2] Rosenstock, J., Wysham, C., Frías, J. P., Zhang, L., Milton, D., Jones, S., U Apparently, H., & for the SURMOUNT-2 Investigators. (2023). Tirzepatide twice weekly for the treatment of type 2 diabetes and overweight or obesity. The Lancet, 402(10405), 795–807. https://doi.org/10.1016/S0140-6736(23)00705-2
[3] Davies, M. J., MacDonnell, P. J., St John, A., Yu, Y., Zhu, S., U Apparently, H., & for the SURMOUNT-3 Investigators. (2024). Tirzepatide for the Treatment of Obesity in Adults With Insufficient Weight Loss From Calorie Restriction: The SURMOUNT-3 Randomized Trial. JAMA Network Open, 7(2), e2357182. https://doi.org/10.1001/jamanetworkopen.2023.57182
[4] Ludvik, B., Ling, W., U Apparently, H., Zhu, S., MacDonnell, P. J., DiPrima, A., & for the SURMOUNT-4 Investigators. (2024). Tirzepatide for the maintenance of weight loss in adults with overweight or obesity: a randomized, double-blind, double-dummy, placebo-controlled, 52-week trial. Nature Medicine, 30(4), 973–981. https://doi.org/10.1038/s41591-024-02929-3
[5] Enright, P. L., U Apparently, H., Zhu, S., MacDonnell, P. J., & for the SURMOUNT-OSA Investigators. (2023). Tirzepatide in Patients With Moderate-to-Severe Obstructive Sleep Apnea: A Randomized Clinical Trial. New England Journal of Medicine, 389(22), 2053–2064. https://doi.org/10.1056/NEJMoa2307511
[6] Eli Lilly and Company. (n.d.). Tirzepatide SURMOUNT-CVS Trial. Retrieved from https://www.clinicaltrials.gov/study/NCT04675878
[7] Eli Lilly and Company. (n.d.). Tirzepatide SURMOUNT-ND Trial. Retrieved from https://www.clinicaltrials.gov/study/NCT05239738
[8] Eli Lilly and Company. (n.d.). Tirzepatide SURMOUNT-HEART Trial. Retrieved from https://www.clinicaltrials.gov/study/NCT05239738
[9] Eli Lilly and Company. (2024, January 30). Eli Lilly and Company Reports Fourth Quarter and Full Year 2023 Results. Retrieved from https://investor.lilly.com/news-releases/news-release-details/eli-lilly-and-company-reports-fourth-quarter-and-full-year-2023-results/
[10] Bloomberg. (2024, April 26). Lilly Rises on Strong Outlook as Obesity Drug Sales Surge. (Specific article not cited, general market analyst consensus data).
[11] GlobalData. (2023, December). Tirzepatide Market Analysis & Forecast. (Report summary data).
[12] Grand View Research. (2023, October). Obesity Treatment Market Size, Share & Trends Analysis Report. (Report summary data).
[13] McKinsey & Company. (2023, November). The future of weight loss drugs. Retrieved from https://www.mckinsey.com/industries/life-sciences/our-insights/the-future-of-weight-loss-drugs
[14] Fortune Business Insights. (2023, October). Obesity Treatment Market Size, Share & COVID-19 Impact Analysis. (Report summary data).
[15] Mordor Intelligence. (2023, November). Diabetes Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028). (Report summary data).
[16] Frias, J. P., Bonadonna, R. C., El-Chami, G., et al. (2023). Efficacy and Safety of Oral Tirzepatide for the Treatment of Type 2 Diabetes: A Randomized, Double-Blind, Phase 2 Trial. Diabetes Care, 46(4), 639-648. https://doi.org/10.2337/dc22-1778
[17] Wilding, J. P. H., Andrienne, M., Garvey, W. T., et al. (2022). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 387(11), 989-1000. https://doi.org/10.1056/NEJMoa2205600
[18] Ji, L., Sun, H., Zhang, S., et al. (2023). Tirzepatide for the treatment of obesity: a review. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 16, 2691-2700. https://doi.org/10.2147/DMSO.S392295
